Tenaya Therapeutics TNYA 深 滬
等待開盤 11-07 09:30:00 美东时间
0.3602
+0.044
+13.99%
華盛通- 最 高0.3636
- 今 開0.3337
- 成交量 290.99万股
- 最 低 0.3311
- 昨 收 0.316
- 總市值 8.21万
- 52周最高 1.46
- 市盈率 靜 --
- 換手率 1.28%
- 52周最低 0.30
- 委 比 93.41%
- 總股本 0.00亿
- 歷史最高 32.00
- 量 比 0.92
- 振 幅 10.28%
- 歷史最低 0.30
- 每 手 1
- 風險率 0.23%
個股概要
財務分析
公司資料
相關新聞
分紅派息
- 分時圖
- 日k
- 周k
- 月k
相關新聞
更多Tenaya Therapeutics收跌0.19%，成交额61.33万美元
11月4日，Tenaya Therapeutics（TNYA）收跌0.19%，报0.36美元，成交额61.33万美元，市值8214.84万美元。 行情数据 •...
11-04 08:05
Tenaya Therapeutics收跌1.76%，成交额87.06万美元
10月28日，Tenaya Therapeutics（TNYA）收跌1.76%，报0.4美元，成交额87.06万美元，市值9148.99万美元。 行情数据 •...
10-28 07:06
Tenaya Therapeutics收跌0.81%，成交额112.29万美元
10月20-22日上海黄浦江畔，2026可持续全球领导者大会再度来袭。诺奖、图灵奖得主现场讲述科技未来与趋势，更有“解救”焦虑、内卷时代的网红教授——麦克法兰与...
10-20 07:12
FDA Grants Regenerative Medicine Advanced Therapy Designation To Tenaya Therapeutics’ TN-401, Gene Therapy Candidate For Treatment Of PKP2-Associated Arrhythmogenic Right Ventricular Cardiomyopathy
RMAT Designation Supported by Positive Interim Data from RIDGE™-1 Phase 1b/2 Clinical Trial of TN-401 which Demonstrated Reduced Arrhythmia Burden Additional Data and Updates on Regulatory Discussions Anticipated in 4Q 2026 SOUTH SAN FRANCISCO, Calif., Sept. 14, 2026 (GLOBE NEWSWIRE) -- Tenaya Ther...
09-14 20:34
Tenaya Therapeutics Q2 EPS $(0.20) Misses $(0.05) Estimate, Sales $1.110M Miss $10.000M Estimate
Tenaya Therapeutics (NASDAQ:TNYA) reported quarterly losses of $(0.20) per share which missed the analyst consensus estimate of $(0.05) by 300 percent. This is a 42.86 percent decrease over losses of $(0.14) per share from the same period last year. The company reported quarterly sales of $1.110 mil...
08-06 06:39
Tenaya Therapeutics to Participate in the Canaccord Genuity 46th Annual Growth Conference
Tenaya Therapeutics announced that its management will host 1x1 investor meetings at the Canaccord Genuity 46th Annual Growth Conference on August 11-12, 2026, in Boston. Eric Hyllengren, Tenaya’s CFO, will participate in a fireside chat on August 11 at 12:30 pm ET. The live webcast and a 30-day replay will be available on Tenaya’s website. Tenaya is a biotech company focused on developing curative therapies for heart diseases, with a pipeline in...
08-04 20:05
Tenaya Therapeutics Reports Inducement Grants under NASDAQ Listing Rule 5635(c)(4)
Tenaya Therapeutics Inc. granted stock options to purchase 1,650,000 shares to its new CFO Eric Hyllengren and 187,200 shares to two new non-executive employees. The options have an exercise price of $0.8365 per share, vesting over four years, and are part of the 2024 Inducement Equity Incentive Plan, in compliance with NASDAQ Listing Rule 5635(c)(4). Tenaya, a biotech company focused on developing curative therapies for heart disease, has a pipe...
07-15 01:00
